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Interleukin-23 (IL-23) and IL-17 are cytokines
currently being targeted in clinical trials. Although
inhibition of both of these cytokines is effective for
treating psoriasis, IL-12 and IL-23 p40 inhibition at-
tenuates Crohn’s disease, whereas IL-17A or IL-17
receptor A (IL-17RA) inhibition exacerbates Crohn’s
disease. This dichotomy between IL-23 and IL-17
was effectively modeled in the multidrug resis-
tance-1a-ablated (Abcb1a/) mouse model of coli-
tis. IL-23 inhibition attenuated disease by decreasing
colonic inflammation while enhancing regulatory
T (Treg) cell accumulation. Exacerbation of colitis
by IL-17A or IL-17RA inhibition was associated with
severe weakening of the intestinal epithelial barrier,
culminating in increased colonic inflammation and
accelerated mortality. These data show that IL-17A
acts on intestinal epithelium to promote barrier func-
tion and provide insight into mechanisms underlying
exacerbation of Crohn’s disease when IL-17A or
IL-17RA is inhibited.
INTRODUCTION
The cytokines interleukin-17 (IL-17) and IL-23 have received sub-
stantial attention over the last decade for their involvement in
inflammatory disease. The IL-17 family of cytokines includes
IL-17A through IL-17F (Moseley et al., 2003). IL-17A is produced
by T helper 17 (Th17) cells, gd T cells, NKT cells, and innate
lymphoid cells (ILCs) and is established as a contributor to
inflammatory responses in many tissues including the skin and
gut (Gaffen et al., 2014; Ouyang et al., 2008). IL-17A signals
through a heteromeric receptor complex consisting of IL-17
receptor A (IL-17RA) and IL-17RC that is widely expressed,
particularly on non-immune cells such as epithelial cells and
fibroblasts (Toy et al., 2006). IL-17RA is an essential receptor
for multiple IL-17 family members including IL-17A, IL-17C,IL-17E, and IL-17F (Ramirez-Carrozzi et al., 2011; Rickel et al.,
2008; Toy et al., 2006; Wright et al., 2008).
IL-23 is a heterodimeric cytokine within the IL-12 cytokine
family. IL-23 and IL-12 share a common p40 subunit, which di-
merizes with IL-23p19 to form IL-23 or with IL-12p35 to form
IL-12. IL-23 signaling contributes to maintenance and pathoge-
nicity of the Th17 cell phenotype and facilitates production of
IL-17A, IL-17F, and IL-22 from T cells and ILCs (Gaffen et al.,
2014). As such, IL-17A production is intimately linked to IL-23R
signaling. IL-23 and IL-17A are elevated in inflammatory bowel
disease (IBD) and SNPs in the IL-23R show strong IBD disease
association (Ahern et al., 2008; Khanna et al., 2014; Kleinschek
et al., 2009).
The IL-23 and IL-17 pathways are currently being targeted by
molecules in the clinic for multiple inflammatory diseases. The
antibody ustekinumab, which neutralizes the shared p40 sub-
unit, is approved to treat psoriasis and is showing benefit in clin-
ical trials for Crohn’s disease (Sandborn et al., 2012). Clinical
data on antibodies specific to IL-23p19 are beginning to emerge
in IBD and also show efficacy (Sands et al., 2015). IL-23-specific
antibodies are highly efficacious in psoriasis, suggesting that the
efficacy achieved with p40 inhibition is a result of IL-23 inhibition
(Tausend et al., 2014). Antibodies to IL-17A or IL-17RA are also
highly efficacious in psoriasis (Gordon et al., 2014; Langley
et al., 2014; Papp et al., 2012), but surprisingly, they exacerbated
Crohn’s disease in a subset of patients (Hueber et al., 2012;
Targan et al., 2012). Thus, although IL-23 is important for pro-
duction and maintenance of IL-17A and IL-17F, inhibition of
IL-17A or IL-17RA in Crohn’s disease patients does not pheno-
copy the effects observed with a p40 or p19 inhibitor. The
mechanism(s) underlying the differential efficacy observed in
Crohn’s disease with inhibition of IL-17 versus IL-23 is an impor-
tant unanswered question.
Many mouse IBD studies have been reported in which the
effects of p40, p19, or IL-17 pathway inhibition were examined.
In most studies, p40 or p19 inhibition was similarly efficacious,
suggesting that IL-23 is the dominant p40-containing cytokine
in colitis models (Ahern et al., 2008; Khanna et al., 2014). In
contrast, the outcome of IL-17 pathway inhibition in mouse IBD
models has been less consistent, with some studies showing
protection and others showing exacerbation (Hundorfean et al.,Immunity 43, 739–750, October 20, 2015 ª2015 Elsevier Inc. 739
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Figure 1. Exacerbation of Abcb1a–/– Colitis
with IL-17RA or IL-17A Inhibition
(A) Time course of average clinical score
assessments ± SEM frommice treatedwith control
IgG1, anti-p40, anti-p19, or anti-IL-17RA.
(B) Time course of average clinical score
assessments ± SEM frommice treatedwith control
IgG1, anti-IL-17A, anti-IL-17E, anti-IL-17F, anti-IL-
17RA, or anti-p19.
Asterisks in (A) and (B) denote statistical signifi-
cance relative to control IgG1 treatment.
(C) Survival curve of mortality of mice treated as
in (B).
(D) Histopathology scoring of H&E-stained colon
sections from mice treated as in (B). The proximal
and distal colons were each scored on a 0–4 scale
and their combined scores graphed. Data points
represent individual mice, and the black bar rep-
resents the group mean. Asterisks denote signifi-
cance relative to control IgG1 treatment.
(E–L) Representative H&E images of colon sam-
ples taken frommice treated with (E) no treatment;
(F) H. bilis + control IgG1; (G) H. bilis + anti-p19;
(H) H. bilis + anti-p40; (I) H. bilis + anti-IL-17RA;
(J) H. bilis + anti-IL-17A; (K) H. bilis + anti-IL-17E;
(L) H. bilis + anti-IL-17F. Images are at 1003 and
the scale bar represents 100 mm.
Data are representative of at least three separate
experiments, with five to ten mice per group.
See also Figures S1–S4.2012; Khanna et al., 2014). In light of these conflicting data, we
sought to identify a mouse model that effectively reproduced
the dichotomy between IL-17 and IL-23 in the gut.
Mice deficient in Abcb1a develop spontaneous colitis that can
be accelerated by infection withHelicobacter bilis (Maggio-Price
et al., 2002; Panwala et al., 1998). Disease susceptibility is
thought to result from an epithelial cell defect (Panwala et al.,
1998). In addition, two studies have reported ex vivo evidence
of a leaky epithelial barrier that precedes the onset of colitis
(Collett et al., 2008; Resta-Lenert et al., 2005). Here, we used
Abcb1a/ mice as a model system to dissect out the mecha-
nisms of IL-23 and IL-17 pathway inhibition in colitis.
RESULTS
Comparison of Efficacywith p40, p19, or IL-17 Inhibitors
in Various IBD Models
To understand the role of IL-23 and IL-17 cytokines in colitis, we
assessed the effects of p40 (IL-12 and IL-23), p19 (IL-23), and740 Immunity 43, 739–750, October 20, 2015 ª2015 Elsevier Inc.IL-17RA inhibition inAbcb1a/mice after
infection with H. bilis. In this model, mice
treated prophylactically with a control
IgG1 antibody had increased clinical signs
of disease throughout the 6 weeks of the
study (Figure 1A). Minimal clinical signs
of disease were observed in mice treated
with either p40 or p19 antibodies (Fig-
ure 1A), demonstrating comparable effi-
cacy with neutralizing IL-12 and IL-23
versus IL-23 alone. In contrast, IL-17RAinhibition significantly exacerbated disease. This antibody,which
blocks IL-17A, IL-17E, and IL-17F, led to rapid onset of disease
and accelerated progression to euthanasia (Figures 1A–1C).
Because IL-17RA is a shared receptor for multiple IL-17 family
members, we sought to determine which IL-17 family member
was responsible for this exacerbating effect. Mice were treated
prophylactically with antibodies specific for IL-17A, IL-17E, or
IL-17F, and their disease courses were compared with anti-IL-
17RA antibody treatment (Figure 1B). Mice treated with IL-17E
and IL-17F antibodies exhibited clinical signs of disease that
were comparable to mice treated with control IgG1. However,
anti-IL-17A treatment increased clinical scores and mortality in
a manner that was comparable to that observed with anti-IL-
17RA treatment (Figures 1B and 1C). The exacerbating effects
observed with anti-IL-17A or anti-IL-17RA were dose dependent
(Figure S1). Histologically, mice in every anti-IL-17 family mem-
ber treatment group had moderate to severe colitis (Figures
1D–1L). If mice were allowed to progress to full disease severity,
the colon pathology appeared comparable with IL-17A or
IL-17RA inhibition relative to control IgG1 treatment (Figures 1D–
1L); however, mice treated with IL-17A or IL-17RA inhibitors
were euthanized much earlier than mice in the other treatment
groups due to their disease severity (Figure 1C), suggesting
that their colon pathology progressed to severe inflammation
much quicker than in the other treatment groups. Indeed,
when amouse from each groupwas taken at the same time point
after infection, the pathology was much worse in mice treated
with anti-IL-17A or anti-IL-17RA than control IgG1 (data not
shown). Together, these findings demonstrate that blockade of
IL-17A specifically, but not IL-17E or IL-17F, leads to exacerba-
tion of clinical signs of disease and mortality in H. bilis-infected
Abcb1a/mice. Treatment with anti-p19 antibody inhibited dis-
ease, revealing a clear dichotomy between the effects of IL-23
and IL-17A signaling in the intestine.
Therapeutic treatment with IL-23 and IL-17RA inhibitors
yielded similar dichotomous results to those observed with
prophylactic treatment (Figure S2). Treatment with p40 or p19
antibodies after the onset of colitis significantly attenuated dis-
ease relative to mice treated with control IgG1 (Figure S2D). In
contrast, mice treated therapeutically with anti-IL-17RA again
showed increased mortality (Figure S2C).
The exacerbating effect of IL-17RA inhibition was unique to
theAbcb1a/model. Exposure of Il17ra/mice to DSS yielded
disease comparable to that of control C57BL/6 mice (Figures
S3A and S3B). Additionally, treatment of C57BL/6 mice with
anti-IL-17RA had no effect on DSS colitis (Figures S3C and
S3D), even in the presence of H. bilis infection (data not shown).
Finally, CB17 scid/scid mice transferred with CB6F1 CD4+
CD45RBhi T cells did not show exacerbation of colitis with pro-
phylactic treatment of anti-IL-17A, IL-17E, IL-17F, or IL-17RA
antibodies (Figure S4). These data demonstrate that the
Abcb1a/ model is uniquely suitable for studying the biology
of IL-17 and IL-23 inhibition as they relate to human IBD.
Inflammatory Gene Expression in the Intestines of Mice
Treated with Anti-IL-17RA Is Increased
To investigate molecular differences between inhibition of p40,
p19, IL-17RA, and IL-17A in the gut of Abcb1a/mice, we con-
ducted transcriptome profiling. Microarray analysis of colon RNA
taken from H. bilis-infected Abcb1a/ mice showed altered
expression of many genes in control IgG1-treated mice relative
to naive, non-diseased, mice (4,078 probes > 2-fold, p < 0.01)
(Figures 2A and S5). Prophylactic treatment with anti-p40 or
anti-p19 normalized gene expression in the colon, consistent
with prevention of colitis (Figures 2C and 2D). In contrast, the
transcriptome profile of mice treated with anti-IL-17A or anti-
IL-17RA was comparable to that of mice treated with control
IgG1, consistent with the histopathology (Figures 2B and S5).
Treatment with p40 and p19 antibodies induced almost identical
gene expression changes, suggesting little to no effect of IL-12
inhibition in this model (Figure S5). Similarly, inhibition of IL-
17RA and IL-17A had virtually indistinguishable transcriptome
profiles, indicating that the effects of IL-17RA inhibition were a
result of IL-17A inhibition (Figure S5).
Although the transcription profiles of anti-IL-17RA and control
IgG1 groups were generally similar, some inflammatory gene
expression wasmore robustly increased with anti-IL-17RA treat-
ment, potentially explaining the observed disease exacerbation.To confirm these differences, changes in the expression of 62
genes were evaluated in the colon by qPCR (Table S1).
H. bilis-infected mice treated with control IgG1 showed
increased cytokine and chemokine expression in the colon
relative to naive uninfected mice, whereas expression of inflam-
matory genes returned to baseline in the presence of an IL-23
inhibitor (Figures 2G–2L and Table S1). Importantly, treatment
of mice with anti-IL-17RA increased expression of many these
analytes, including Tnf, Il6, Ifng, Ccl3, Cxcl10, and Mmp13,
suggesting worsened colonic inflammation. Treatment of mice
with anti-IL-17A yielded similar qPCR results to anti-IL-17RA
treatment (data not shown).
IL-17RA and IL-23p19 Inhibition Alters Immune Cell
Populations in the Colon
To determine the effects of IL-17RA and p19 inhibition on intes-
tinal cellularity, we isolated cells from the lamina propria of mice
with disease and analyzed them by flow cytometry. Diseased
mice treated with control IgG1 had significantly increased
CD45+Gr-1+ neutrophil and macrophage numbers and CD45+
CD3+ T cell numbers in the colon (Figures 3A and 3B). Treatment
with anti-IL-17RA reduced the numbers of Gr-1+ cells in the
colon relative to control IgG1-treated mice, consistent with the
known role of IL-17 in promoting neutrophil recruitment. Cell
numbers in mice treated with anti-p19 antibody were compara-
ble to those observed in naive mice, consistent with the low dis-
ease score in these mice.
Because IL-23 has direct effects on T cells, including induction
of IL-17A and interferon-g (IFN-g), we intracellularly stained
T cells isolated from the lamina propria of colitic mice for IL-
17A and IFN-g. Colitis in control IgG1-treated mice was associ-
ated with increased IFN-g and IL-17A production from CD4+
T cells (Figure 4A). IL-17RA inhibition nearly doubled the accu-
mulation of IL-17A+IFN-g+ double-positive CD4+ T cells whereas
p19 inhibition decreased double-positive T cells to almost naive
quantities.
Intracellular staining for Foxp3 was conducted to enumerate
regulatory T (Treg) cells. The percentage of CD25+ Foxp3+
colonic Treg cells was slightly reduced in mice treated with con-
trol IgG1 and was further reduced by almost 50% inmice treated
with anti-IL-17RA relative to naive mice (Figure 4B). In contrast,
p19 inhibition increased the percentage of Treg cells in the colon,
and importantly, increased the ratio of Foxp3+ cells to effector
IL-17A+ or IFN-g+ cells, consistent with a more suppressive
environment (Figure 4C).
Exacerbation of Colitis with Anti-IL-17RA Treatment
Is Not Dependent on IFN-g
Given the increased colonic production of IFN-g and tumor
necrosis factor a (TNF-a) after IL-17RA antibody treatment as
evidenced by qPCR (Figure 2), as well as the potential counter-
regulation between Th17 and Th1 cells, we sought to determine
whether exacerbation of disease with IL-17RA inhibition was due
to an increase in Th1 cell activity. Therefore, we examined
whether IFN-g was important for disease exacerbation. Prophy-
lactic treatment of H. bilis-infected Abcb1a/ mice with anti-
IFN-g antibody inhibited colitis development as effectively
as anti-p19 treatment (Figures 5A and 5B), demonstrating
that IFN-g is an important cytokine in this model. CombinedImmunity 43, 739–750, October 20, 2015 ª2015 Elsevier Inc. 741
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Figure 2. Colonic Gene Expression Changes in H. bilis-Infected Abcb1a–/– Mice Are Reduced by Prophylactic Inhibition of IL-23 but not
IL-17RA or IL-17A
(A–D) Comparison of treatment with (A) control IgG1, (B) anti-IL-17RA, (C) anti-p40, and (D) anti-p19 to naive uninfected mice.
(E) Anti-p19 and anti-p40 groups have similar expression profiles.
(F) Anti-IL-17RA and anti-IL-17A groups have similar expression profiles. Messenger RNA was extracted from colon tissue taken at necropsy, and gene
expression was assessed by microarray. Fold change for each group relative to non-diseased naive mice is plotted relative to significance. A 2-fold change and
p value of 0.01 are indicated by red lines. See also Figure S5.
(G–L) Comparison of H. bilis-infected Abcb1a/ mice treated with control IgG1, anti-IL-17RA, anti-p40, or anti-p19 to naive uninfected mice. Messenger RNA
was extracted from colon tissue taken at necropsy. Expression of colonic (G) Tnf, (H) Il6, (I) Ifng, (J) Ccl3, (K) Cxcl10, and (L) Mmp13 as measured by qPCR.
Graphs depict average expression ± SEM. Asterisks represent statistical significance relative to anti-IL-17RA treatment. Data are representative of greater than
three separate experiments with four to six mice per group. See also Table S1.
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Figure 3. Changes in Colon Immune Cell Populations Observed with Protective or Exacerbating Treatments
H. bilis-infected Abcb1a/mice were treated with control IgG1, anti-IL-17RA, or anti-p19. At necropsy, colon tissue was digested for LPMC isolation and flow
cytometry analysis. Colon (A) CD45+Gr-1+ and (B) CD45+CD3+ cell numbers were determined by flow cytometry. Graphs depict average numbers ± SEM.
Asterisks represent statistical significance relative to anti-IL-17RA treatment. Data are representative of at least three separate experimentswith two to eightmice
per group.treatment of mice with anti-IFN-g and anti-IL-17RA antibodies
did not prevent colitis development, and mice treated with
both antibodies had exacerbated disease relative to control
IgG1-treated mice (Figures 5C–5G). Disease development was
slightly delayed with co-treatment versus anti-IL-17RA antibody
treatment alone, but ultimately, the neutralization of IL-17RA
negated the protective effect of IFN-g inhibition. This suggests
that a shift in the Th17 and Th1 cell balance is not key to disease
exacerbation seen with IL-17A or IL-17RA inhibition, and impor-
tantly, shows that the effects of blocking IL-17RA are dominant.
IL-17RA Inhibition Adversely Influences Intestinal
Epithelial Permeability and Function
We next explored whether IL-17RA inhibition was affecting
intestinal epithelial permeability in vivo. Indirect measurements
of epithelial barrier breach and systemic microbial exposure
involved assessing serum concentrations of soluble CD14
(sCD14) and lipopolysaccharide (LPS) binding protein (LBP)
(Lakatos et al., 2011; Pastor Rojo et al., 2007). Both sCD14
(Figure 6A) and LBP (Figure 6B) were minimally detected in
the serum of naive animals and were significantly increased in
colitic control IgG1-treated animals, suggesting a breach in the
intestinal epithelial barrier. For both analytes, IL-17RA inhibition
increased serum accumulation beyond that observed with
control IgG1 treatment, whereas p19 inhibition normalized
them. IL-17A inhibition induced LBP and sCD14 accumulation
similarly to IL-17RA inhibition (data not shown).
To more directly study epithelial permeability, mice were
dosed orally with a cocktail of lactulose, mannitol, and sucralose,
and plasmawas collected 4 hr later for quantitation of sugar pas-
sage from the digestive tract into the circulation. Such methods
have been used in mice and humans to gauge the ‘‘leakiness’’ of
the gut and correlate with disease severity and relapse (Noth
et al., 2012; Olson et al., 2006; Wild et al., 2003). Sugar dosing
was done at the first clinical signs of colitis (early time point) or
at the standard terminal endpoint (late time point). Sucralose, a
sugar used to detect permeability in the small and large intestine,
was elevated in the plasma of control IgG1-treated mice at the
early time point and was further increased about 2-fold by thelate time point (Figure 7A). Relative to control IgG1 treatment,
anti-IL-17RA treatment increased sucralose accumulation at
the early time point and significantly increased it at the later
time point. Treatment with anti-p19 antibody hadminimal effects
on sucralose passage at the early time point, but at the late time
point, significantly improved permeability over control IgG1-
treated mice. Identical results were obtained for lactulose (Fig-
ure 7B), a marker of small intestinal tight junction integrity, and
mannitol (Figure 7C), amarker of small intestine passive diffusion
and surface area.
Alterations in epithelial cell function were further assessed
by measuring expression changes of genes associated with
epithelial barrier function, tight junction integrity, and differentia-
tion (Figures 7D–7F and Table S2). Colitis was associated with
an increase in the expression of Cldn4 (Figure 7D), a marker of
wounded epithelium (Seno et al., 2009). Cldn4 expression was
increased in anti-IL-17RA-treated mice relative to all other
treatment groups, particularly at the late time point. Anti-p19
maintained Cldn4 expression significantly lower at both time
points. Colitis was also associated with decreases in the expres-
sion of both Pigr (Figure 7E), whose protein product is involved
in IgA transport, and Lgr5, a marker of crypt regenerative stem
cells (Figure 7F; Barker et al., 2007; Cao et al., 2012). Expression
of these genes was further decreased by anti-IL-17RA treat-
ment, whereas p19 inhibition restored expression comparable
to naive mice by the later time point. Despite the loss of Lgr5
expression, mice treated with anti-IL-17RA did not have reduced
crypt proliferation, and instead had increased Ki67 staining along
the length of the crypts, in line with what is commonly observed
in terminally colitic control IgG1-treated mice (Figure S6).
Antimicrobial peptides such as Defb1, Reg3g, and S100a8
increased in expression as colitis progressed (Figures 7G–7I).
Anti-IL-17RA treatment nearly eliminated all Defb1 expression
at early and late time points and reduced Reg3g and S100a8
at the later time points, consistent with the known role of
IL-17A in induction of anti-microbial peptides. Additionally,
inflammatory cytokine and chemokine production was en-
hanced with IL-17RA inhibition, primarily at the early time point
(Table S3), and reducedwith p19 antibody treatment. In all, theseImmunity 43, 739–750, October 20, 2015 ª2015 Elsevier Inc. 743
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Figure 4. IL-23 Inhibition and IL-17RA Inhibition Have Opposing Effects on Intestinal Effector and Regulatory T Cell Accumulation
H. bilis-infected Abcb1a/ mice were treated with control IgG1, ant-IL-17RA, or anti-p19. At necropsy, colon tissue was digested for LPMC isolation and flow
cytometry analysis.
(A) Cells were restimulated with PMA and ionomycin, and the intracellular accumulation of IFN-g and IL-17A was assessed in CD3+CD4+ cells.
(B) CD3+CD4+ lamina propria cells were gated for CD25 and FoxP3 to quantitate Treg cells.
(C) The ratio of the absolute number of FoxP3+ cells to the number of IL-17A+ or IFN-g+ cells was determined. Bar graphs depict average ± SEM. Asterisks
represent statistical significance relative to anti-p19 treatment. Data are representative of two separate experiments with three to eight mice per group.data suggest that IL-17RA inhibition significantly weakens intes-
tinal epithelial barrier function through modulation of epithelial
cell-related genes involved in formation of tight junctions, cellular
regeneration, and antimicrobial defense whereas IL-23 inhibition
normalized these same parameters to baseline. Taken together,
these data support a role for intestinal IL-17 in neutrophil recruit-
ment, anti-microbial peptide expression, andmaintenance of the
epithelial barrier. In contrast, IL-23 leads to the production of a
number of cytokines and chemokines, the development of path-
ogenic IL-17A+IFN-g+ double-positive cells, and inhibition of
regulatory T cell generation, all leading to increased inflamma-
tion and subsequent destruction of the epithelial barrier.744 Immunity 43, 739–750, October 20, 2015 ª2015 Elsevier Inc.DISCUSSION
The use of the Abcb1a/model of colitis has empowered initial
dissection of the mechanisms behind the differential outcomes
of p40 versus IL-17A and IL-17RA inhibition in Crohn’s disease.
As observed in human Crohn’s disease patients, we saw inhibi-
tion of colitis with p40 neutralization (Sandborn et al., 2012) and
exacerbation of colitis with IL-17A or IL-17RA inhibition (Hueber
et al., 2012; Targan et al., 2012). The protective effects observed
with p40 inhibition were recapitulated with inhibition of IL-23
alone, consistent with the recently reported clinical benefit
seen with p19 inhibition in Crohn’s disease (Sands et al., 2015).
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Figure 5. Inhibition of IFN-g Does Not Inhibit Disease Development in the Presence of IL-17RA Inhibition
(A) Time course of average clinical score assessments ± SEM frommice treated with control IgG2a, anti-IFN-g, anti-p19, or vehicle. Asterisks represent statistical
significance relative to control IgG2a treatment.
(B) Histopathology scoring of H&E-stained colon sections from mice treated as in (A). The proximal and distal colons were each scored on a 0–4 scale and their
combined scores graphed. Each data point represents an individual mouse, and the black bar represents the group mean. Asterisks represent statistical sig-
nificance relative to control IgG2a treatment.
(C) Time course of average clinical score assessments ± SEM from mice treated with anti-IL-17RA in combination with control IgG2a or anti-IFN-g. Asterisks
represent statistical significance relative to anti-IL-17RA + control IgG2a treatment.
(D–G) Representative images of H&E-stained colon sections from the mice treated with H. bilis and (D) anti-p19, (E) anti-IFN-g + control IgG1, (F) anti-IL-17RA +
control IgG2a, and (G) anti-IFN-g+ anti-IL-17RA. Images are at 1003 and the bar represents 100 mm.Data are representative of at least two separate experiments
with five to ten mice per group.IL-17RA inhibition augmented disease through multiple ave-
nues. First, the accumulation of neutrophils in the intestine was
reduced. IL-17A induces the production of chemokines that
are potent neutrophil chemoattractants, such as CXCL8 and
CXCL1 (Lee et al., 2008). Neutrophils are an important defense
against microbial exposure, and poor recruitment could exacer-
bate disease by facilitating bacterial invasion and dispersal
(Smith et al., 2009).
IL-17RA inhibition also increased the generation of IFN-g+IL-
17+ double-positive effector cells. IFN-g+IL-17+ coproducing
CD4+ T cells are specifically enriched in the inflamed intestinal
mucosa in Crohn’s disease and ulcerative colitis patients, and
coproduction of these cytokines has been identified as a hall-
mark of pathogenic Th17 cells in murine models and humans
(Ahern et al., 2010; Globig et al., 2014; Kleinschek et al., 2009;
Ramesh et al., 2014). Ultimately, the environment in the colonofmice treatedwith IL-17A or IL-17RA inhibitors becomes tipped
in favor of effector T cells over regulatory T cells, further facili-
tating intestinal inflammation.
Perhaps most strikingly, IL-17RA inhibition promoted break-
down of the intestinal epithelial barrier. Indirect (sCD14 and
LBP) and direct (lactulose, mannitol, sucralose) barrier integrity
measurements have been used to monitor the leakiness of the
gut barrier in humans and animals and are associated with dis-
ease progression and relapse (Lakatos et al., 2011; Noth et al.,
2012; Olson et al., 2006; Pastor Rojo et al., 2007). With these
measurements, we observed an increase in intestinal perme-
ability in the presence of IL-17RA inhibition, well beyond what
normally occurs in the diseased state. Even at the first signs of
colitis, the sugar permeability in mice treated with anti-IL-17RA
was equivalent to the end-stage permeability in control IgG1-
treated mice. Few studies have addressed the effects of IL-17Immunity 43, 739–750, October 20, 2015 ª2015 Elsevier Inc. 745
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Figure 6. IL-17RA Inhibition Augments
Indirect Measurements of Epithelial Barrier
Function
Plasma taken from H. bilis-infected Abcb1a/
mice treated with control IgG1, anti-IL-17RA, or
anti-p19 was analyzed for (A) soluble CD14 or (B)
LPS binding protein by ELISA. Graphs depict the
average ± SEM for each analyte. Asterisks repre-
sent statistical significance relative to anti-IL-17RA
treatment. Data are representative of at least two
experiments with five to ten mice per group.family cytokines on epithelial barrier function. However, an early
study indicated that IL-17A could enhance barrier function of T84
epithelial cell monolayers in vitro (Kinugasa et al., 2000). Here, we
have presented in vivo evidence that IL-17RA signaling can influ-
ence intestinal epithelial barrier permeability.
Reduced barrier integrity coincided with alterations in epithe-
lial-cell-associated gene expression. Increased Cldn4, as seen
with IL-17RA inhibition, is indicative of wounded epithelium or
altered tight junction formation (Seno et al., 2009). Loss of Pigr
suggests an altered ability to translocate protective IgA in the
gut, which is important for neutralizing exposure to intestinal
microbes. IL-17A was previously shown to regulate Pigr on
epithelial cells, and loss of this protein contributed to exacer-
bated colitis in mice (Cao et al., 2012). Decreased Lgr5
suggested a loss of stem cells or reduced Wnt signaling in the
crypts; however, there was no apparent loss of proliferative
capacity. This might be explained by activation of quiescent
stem cells or increased production of cytokines such as IL-22
that can stimulate proliferation independent of stem cells. Addi-
tionally, IL-17RA inhibition reduced expression of antimicrobial
peptides in the gut, which would facilitate microbial persistence
and invasion. Although it is difficult to conclude which of the
alterations are due to a direct effect of IL-17A on epithelial cells
in this model, dissection of these pathways in primary intestinal
organoid cultures will help determine which of these pathways
is most influenced by IL-17RA signaling. Our data support a
model in which blockade of the IL-17 pathway in colitis weakens
intestinal epithelial barrier function, resulting in an inappropriate
exposure of immune cells in the lamina propria to microbes, acti-
vation of these cells, and induction of an inflammatory response.
Combined with poor innate cell recruitment and Treg cell accu-
mulation, a more rapidly progressing inflammatory response
ensues.
If IL-17 inhibition is affecting epithelial cell function, one might
expect that all mouse models would show exacerbation with
IL-17 blockade. It was difficult to find a suitable model to study
the exacerbation induced by IL-17A or IL-17RA inhibition in
Crohn’s disease because some of the most commonly used
models, including DSS colitis and the T cell transfer model,
do not consistently show exacerbation. The Abcb1a/ model,
as used in this study, includes both a genetic susceptibility and
infection component, both of which might be necessary to see
exacerbation. In the absence of H. bilis, inhibition of IL-17RA
resulted in an accelerated disease onset in Abcb1a/ mice,
although it was milder compared to mice treated with H. bilis
(data not shown), demonstrating that the infectious agent con-746 Immunity 43, 739–750, October 20, 2015 ª2015 Elsevier Inc.tributes to the disease exacerbation but is not essential. It is
noteworthy that in Crohn’s disease patients treated with IL-17 in-
hibitors, a subset of patients showed exacerbation. This subset
of patients might possess a genetic susceptibility and/or an
altered intestinal microbiome that enabled disease exacerbation
upon IL-17A or IL-17RA inhibition. Indeed, a number of genes
involved in intestinal epithelial cell function are genetically asso-
ciated with IBD and patients with Crohn’s disease and ulcerative
colitis have shifts in their intestinal microbial composition. These
data suggest that a number of beneficial roles exist for IL-17
in the gut in the context of controlling microbial exposure and
disease susceptibility, including induction of anti-microbial
peptides, recruitment of neutrophils, and maintenance of the
epithelial barrier.
In contrast to the effects of IL-17 inhibition, IL-23 inhibition
was efficacious in preventing colitis in Abcb1a/ mice. IL-23
is established as a trigger of robust inflammatory responses in
the gut and is known to be rapidly produced upon exposure to
microbes (Izcue et al., 2008). IL-23 stimulates T cells and ILCs
to induce not only IL-17A and IL-17F, but also TNF-a, granulo-
cyte macrophage colony stimulating factor (GM-CSF), and
several chemokines, leading to induction of an immune
response and infiltration of T cells and neutrophils (Gaffen
et al., 2014).
Th17 cells are increased in Crohn’s disease patients and are a
pathogenic cell type in various mouse disease models (Ahern
et al., 2008, 2010; Gaffen et al., 2014; Khanna et al., 2014; Klein-
schek et al., 2009). Data are accumulating to demonstrate that
the distinctive feature of pathogenic Th17 cells is cellular respon-
siveness to IL-23, not IL-17A production, per se. Th17 cells
exposed to transforming growth factor-b (TGF-b) and IL-6, but
not IL-23, produce IL-17 and IL-10 and do not induce inflamma-
tion, whereas Th17 cells exposed to IL-23 are pathogenic
(McGeachy et al., 2007). Additionally, pathogenic autoreactive
murine Th17 cells are characterized by a molecular signature
that includes substantial expression of IL-23R (Lee et al.,
2012). Similarly, a proinflammatory human Th17 cell subset
was recently described that expresses IL-23R, produces both
IFN-g and IL-17, and shows increased responsiveness to IL-23
(Ramesh et al., 2014). IFN-g+IL-17A+ cells are specifically en-
riched in the inflamed mucosa of IBD patients (Globig et al.,
2014), lending credence to the hypothesis that these are the
pathogenic T cell type in IBD. If so, IL-23 inhibition should be
efficacious in targeting this cell type.
In addition to an elimination of these IFN-g+IL-17A+ double-
producing cells, the percentage of Treg cells in the colon
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Figure 7. Inhibition of IL-17RA Exacerbates Intestinal Epithelial Barrier Dysfunction
H. bilis-infected Abcb1a/mice were treated with control IgG1, anti-IL-17RA, or anti-p19. Mice were euthanized at the first clinical signs of disease (early) or at
the standard terminal endpoint (late). Direct measurement of barrier function was assessed by dosing with (A) sucralose, (B) lactulose, and (C) mannitol.
Accumulation of each of the sugars in the plasma 4 hr later was quantitated by LCMSMS. RNA was prepared for qPCR analysis from colon tissue taken from the
same mice as above. Expression of (D) Cldn4, (E) Pigr, (F) Lgr5, (G) Defb1, (H) Reg3g, and (I) S100a8 are shown. Bar graphs represent average values ± SEM.
Asterisks represent statistical significance relative to anti-IL-17RA treatment. Data are representative of at least two separate experiments with five to ten mice
per group. See also Figure S6 and Tables S2 and S3.increased with IL-23 inhibition, suggesting that blockade of
IL-23 not only inhibited inflammation, but promoted a more
suppressive environment. In fact, the Treg:Teff cell ratios
relative to both IL-17A+ and IFN-g+ cells were significantly
elevated with IL-23 inhibition. This antagonistic effect of IL-23
on Treg cells has been described in other in vivo settings
(Izcue et al., 2008). The data from our model suggest that
the beneficial effects of antibodies to p40 or p19 in clinical trials
for Crohn’s disease might be a result of interfering with at
least three IL-23-mediated mechanisms: increased inflamma-
tory cytokine production, increased IFN-g+IL-17A+ double-pos-
itive T cell accumulation, and decreased Treg cell function or
accumulation.
The effects of cytokine inhibition reported in this study eluci-
date the differential effects of these antagonists in the clinic for
psoriasis and IBD. Psoriasis is characterized by acanthosis, aseverely thickened epidermal layer, and this is dramatically
resolved with IL-17A, IL-17RA, and IL-23 inhibition. In IBD,
the intestinal epithelial layer is leaky and damaged, and in
severe cases, lost altogether. The response of the skin and
intestinal epithelium to IL-17A might be similar, in promoting
epithelial integrity and antimicrobial defense. In the gut, this is
beneficial, whereas in the skin, these same responses instead
contribute to acanthosis and local tissue damage. IL-23 in-
duces many other inflammatory cytokines in addition to IL-17,
and in the gut, the beneficial effect of IL-17A production
might be overshadowed by the overwhelming production
of various other inflammatory cytokines and suppression of
Treg cell responses driven by IL-23. This study suggests that
even though IL-17 inhibitors are not efficacious in Crohn’s
disease, inhibition of IL-23 is a promising therapeutic approach
for IBD.Immunity 43, 739–750, October 20, 2015 ª2015 Elsevier Inc. 747
EXPERIMENTAL PROCEDURES
Mice and Reagents
Female mice deficient in multiple drug resistance (mdr)1a (MDR1A,
FVB.129P2-Abcb1atm1BorN7) were obtained from Taconic. Colitis studies
were initiated with mice at 7–9 weeks of age. Mice were cared for in accor-
dance to the Guide for the Care and Use of Laboratory Animals. Animals
were group housed at an AAALAC-accredited facility in ventilated micro-
isolator housing on corn cob bedding. Animals had ad libitum access to
pelleted feed and water via water bottle. Animals were maintained on a
12:12 hr light: dark cycle and had access to enrichment opportunities. All
research protocols were approved by the Institutional Animal Care and Use
Committee.
Neutralizing antibodies to cytokines and cytokine receptors were all gener-
ated at Amgen Inc. Anti-mouse IL-17A (clone M210), anti-mouse IL-17E (clone
M819), anti-mouse IL-17F (clone M850), anti-mouse IL-17RA (clone M751),
anti-mouse p40 (clone C17.8), and anti-mouse p19 (clone 16E5) were all
dosed at 500 mg i.p. once per week. All antibodies were mouse IgG1 and
the control used for these was clone 4D2, which was injected at 500 mg i.p.
once per week. Anti-mouse IFN-g, clone Mu811RaxMu, was dosed at
500 mg i.p. twice per week, as was its isotype control mouse IgG2a antibody,
clone mAb50.
Induction and Treatment of Colitis in Abcb1a–/– Mice
One group of Abcb1a/mice was given Brucella broth by oral gavage on day
0 and 7. In some studies, these mice were maintained for the duration of the
study to allow for examination of spontaneous disease. In other studies, these
mice were euthanized within 2–3 weeks to allow for naive tissue collection.
The remaining mice in each study were infected with 107 CFU of Helicobacter
bilis bacteria by oral gavage on days 0 and 7 to accelerate colitis develop-
ment. For prophylactic treatment studies, mice were treated with antagonist
antibodies beginning on day 0 and continuing on a regular schedule
thereafter.
Mice were monitored at least twice weekly for weight loss and clinical signs
of disease. Clinical symptoms were scored based on stool consistency
(0, normal; 1, moist/sticky; 2, soft; 3, diarrhea; 4, bleeding) and anal inflamma-
tion (0, none; 1, mild; 2, moderate; 3, severe; 4, rectal prolapse). Scores for
each mouse were summed to achieve a maximal score of 8. Any mouse that
was euthanized before the end of the study was given a score of 8 and its final
weight held constant for the duration of the study. At necropsy, mice were
euthanized with carbon dioxide followed by cervical dislocation. Blood was
collected by cardiac puncture for serum or plasma isolation. Proximal and
distal colon was fixed in formalin for H&E analysis and the middle colon was
snap frozen in liquid nitrogen for RNA or protein isolation.
Epithelial Permeability Assessment from Plasma Samples
To indirectly assess epithelial permeability, serum or plasma samples were
analyzed for soluble CD14 by ELISA (R&D Systems) or for lipopolysaccharide
binding protein (LBP) by ELISA (Antibodies Online).
To directly assess intestinal epithelial permeability, mice were dosed with
200 ml of a cocktail of lactulose (60 mg/ml), mannitol (40 mg/ml), and sucralose
(30 mg/ml) by oral gavage, using published methods (Olson et al., 2006). All
sugars were obtained from Sigma. Four hours after gavage, mice were eutha-
nized and blood was collected by cardiac puncture into BD Microtainer tubes
with lithium heparin (Becton Dickinson) for plasma isolation. Sugars were
quantitated in the plasma by LCMSMS.
HPLCMSMS Analysis
Aliquots of mouse plasma were spiked with sucralose (64 mM), mannitol
(640 mM), or lactulose (128 mM) and then serial diluted to produce standard
curves. Aliquots of mannitol and lactulose standards along with the unknown
samples were placed into a 96-deep-well plate and treated with acetonitrile
with 1 mM of sucrose-13C12 (internal standard; Sigma). Aliquots of sucralose
standards along with the unknown samples were placed into a 96-deep-well
plate and treated with of acetonitrile containing 1 mMof sucralose-2H6 (internal
standard; Toronto Research Chemicals). Samples were centrifuged and the
supernatants transferred to fresh 96-deep-well plates and evaporated over
nitrogen at room temperature in a TurboVap (Zymark). The mannitol and748 Immunity 43, 739–750, October 20, 2015 ª2015 Elsevier Inc.lactulose samples were reconstituted in acetonitrile with 0.1% formic acid
(v,v). The sucralose samples were reconstituted in water with 0.1% formic
acid (v,v). The samples were transferred to a 96-shallow-well plate for
HPLCMSMS analysis.
Samples were analyzed by electrospray ionization (ESI) in the negative ion
mode using multiple reaction monitoring (MRM) on a Sciex API 4000Q triple
quadrupole 2-D linear ion trap hybrid mass spectrometer (AB Sciex). For anal-
ysis of mannitol and lactulose, a hydrophilic interaction liquid chromatography
(HILIC) system was employed using a Luna NH2, 2.0 3 30 mm 5 mm column
(Phenomenex). For analysis of sucralose, a reverse phase system was em-
ployed using an Allure pentafluorophenyl propyl (PFPP), 2.1 3 50 mm 5 mm
column (Restek).
RNA Isolation
Snap frozen colon tissue was homogenized with a Tissuelyser (QIAGEN). Total
RNA was extracted from the lysate using the RNeasy Mini kit (QIAGEN) with
an on-column DNase digestion step. RNA integrity was assessed using a
Bioanalyzer 2100 and the concentration measured on an ND-1000 Spectro-
photometer (NanoDrop).
Microarray Analysis
Total RNA was amplified on an ArrayPlex (Beckman Coulter) using the Ovation
RNA Amplification System V2 and WB reagent (Nugen). Amplified cDNA was
labeled using the FL Ovation cDNA Biotin Module V2 (Nugen) according to
manufacturer recommendations. The labeled cDNA was hybridized onto
Affymetrix mouse MG430_PM arrays (Affymetrix) and processed according
to Affymetrix technical protocols. The resulting data were analyzed using Array
Studio (Omicsoft).
Quantitative RT-PCR
Total RNA was reverse transcribed using the High-Capacity cDNA Reverse
Transcription Kit (Applied Biosystems) with random hexamer primers.
Expression of multiple genes was assessed using pre-designed Taqman
Gene Expression assays from Applied Biosystems in low-density arrays on a
7900HT Fast Real Time PCR System. Average raw cycle threshold (Ct) data
were normalized to the expression of HPRT.
Cellular Enumeration and Phenotyping from Colon Tissue
Mouse colons were digested twice with 2 mM EDTA at 37C for 20 min. The
epithelial fraction was discarded, and the remaining cells were digested with
collagenase IV (Sigma) and DNase (Roche) at 37C for 30 min. Cells were
collected at the interface of 44%/67% Percoll gradient (Sigma).
For flow cytometry analysis, cells were stained with antibodies from Becton
Dickinson, eBioscience, or BioLegend. To detect intracellular cytokine pro-
duction, cells were incubated at 37C for 4–5 hr in the presence of PMA and
ionomycin and GolgiStop (Becton Dickinson).
Histopathology Assessment
FFPE colons were processed and stained with H&E according to standard
procedures. Tissues were scored on a 0–4 system: 0, normal; 1, mild inflam-
mation, focal enterocyte hyperplasia; 2, moderate inflammation, multifocal
enterocyte hyperplasia, goblet cell loss; 3, moderate inflammation, diffuse
enterocyte hyperplasia, few goblet cells; 4, severe inflammation, diffuse enter-
ocyte hyperplasia, mucosal ulceration.
Statistical Analysis
Statistical analyses were performed with GraphPad Prism v.6.00 for Windows
(GraphPad Software). For quantitative data, one-way ANOVA with Dunnett’s
post-test was used. For categorical data, Kruskal-Wallis test or Friedman
test with Dunn’s post-test was used. Statistical significance is demonstrated
in the graphs by asterisks: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
ACCESSION NUMBERS
Microarray data are deposited under GEO accession number GEO:
GSE72212.
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Supplemental Information includes six figures and three tables and can be
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